Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(33%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
5
56%
Ph not_applicable
1
11%
Ph phase_3
1
11%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)
Other(2)

Detailed Status

Active, not recruiting2
unknown2
Completed2
Terminated1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 25 (55.6%)
Phase 31 (11.1%)
N/A1 (11.1%)

Trials by Status

terminated111%
active_not_recruiting222%
unknown222%
withdrawn111%
completed222%
recruiting111%

Recent Activity

3 active trials
Showing 5 of 9
active_not_recruitingphase_1

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824
active_not_recruitingphase_1

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347
recruitingphase_2

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

NCT04183712
unknownphase_3

HAIC Versus Systemic Chemotherapy for Unresectable ICC

NCT03771846
withdrawnphase_2

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

NCT01524575
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04542824Phase 1

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Active Not Recruiting
NCT04663347Phase 1

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Active Not Recruiting
NCT04183712Phase 2

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Recruiting
NCT03771846Phase 3

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Unknown
NCT01524575Phase 2

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Withdrawn
NCT00159458Phase 2

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Terminated
NCT00504192Phase 2

A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Completed
NCT00250822Phase 2

Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

Completed
NCT01125020Not Applicable

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9